article thumbnail

Breakthrough drug candidates and cancer treatment innovations

Drug Target Review

It also supports the argument for developing ZW171 for the treatment of other MLSN-expressing solid tumours. What is the significance of ZW191 demonstrating strong responses in FRα-low expressing PDX models for the treatment of oncology indications with lower levels of FRα?

Treatment 100
article thumbnail

Applications of engineered exosomes in drugging noncoding RNAs for cancer therapy

Chemical Biology and Drug Design

lncRNA, miRNA, siRNA, receptors, and proteins) are added to exosomes which are released from the parental cells. Abstract Noncoding RNAs (ncRNAs) are engaged in key cell biological and pathological events, and their expression alteration is connected to cancer progression both directly and indirectly.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

MicroRNA?577/EIF5A2 axis suppressed the proliferation of DDP?resistant nasopharyngeal carcinoma cells by blocking TGF?? signaling pathway

Chemical Biology and Drug Design

Effects of circ_0002375 on cisplatin-resistant NPC cells: After cisplatin treatment, circ_0002375 knockdown was transfected into cisplatin-resistant SUNE1/5-8F cells, which led to the inhibition of cisplatin resistance via down-regulating EIF5A2 that mediated by up-regulated miR-577.

article thumbnail

Thalidomide suppresses migration and invasion of colorectal cancer cells by inhibiting HOXB7?mediated activation of the Wnt/??catenin signaling pathway

Chemical Biology and Drug Design

Following the treatment of 0, 1.94, 7.75, or 19.36 μM μM THA, CRC cell viability, apoptosis, migration, and invasion were evaluated by methyl tetrazolium, flow cytometry, wound-healing, and transwell assays. μM THA dwindled CRC cell viability, migration, and invasion, and facilitated apoptosis.

article thumbnail

Building better brain models for Parkinson’s disease and beyond

Drug Target Review

The search for effective treatments for neurodegenerative diseases like Parkinson’s disease has long been hindered by the brain’s complexity and the absence of adequate models for drug discovery. This approach has the potential to revolutionise clinical trial design and lead to more effective, personalised treatments.

Disease 52
article thumbnail

CAR-NK cells: promising for cancer therapy

Drug Target Review

Only three of the CAR-NK studies were for the treatment of solid tumours. The non-CAR-NK studies showed very good safety data when compared to neurological and cytokine storm responses reported for CAR-T cell trials. Three patients were treated with 2-6 doses of 2×10 7 to 2×10 9 cells.

Therapies 118
article thumbnail

Patient-derived organoids in disease modelling

Drug Target Review

As we explore translatability, technological advancements and the integration of artificial intelligence (AI), we envision the potential role of PDOs throughout the entire medicine creation pipeline, from target identification to personalised clinical treatments, ultimately reducing costs and improving patient outcomes.

Disease 122